21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
3 citations,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
68 citations,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.